Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of nafronyloxalate in preparing medicine for treating or preventing influenza virus

A technology of naftifiramide oxalate and prevention of influenza, which is applied in the field of medicine, can solve the problem that naftofuramide oxalate has no anti-influenza virus, and achieve broad-spectrum antiviral activity and good safety

Inactive Publication Date: 2014-04-02
武汉威立得生物医药有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But so far, no relevant reports about the anti-influenza virus of naftifiramide oxalate have been found.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of nafronyloxalate in preparing medicine for treating or preventing influenza virus
  • Application of nafronyloxalate in preparing medicine for treating or preventing influenza virus
  • Application of nafronyloxalate in preparing medicine for treating or preventing influenza virus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Embodiment 1: the evaluation of anti-influenza virus activity of nafuramide oxalate

[0034] 1. Experimental Materials

[0035] 1.1 Cells, viruses and drugs

[0036] MDCK cells were purchased from ATCC, virus A / PuertoRico / 8 / 34 (H1N1) was amplified from chicken embryo culture, and naftofuramide oxalate was purchased from Sigma.

[0037] 1.2 Experimental Instruments

[0038] Multifunction detector PerkinElmer, inverted microscope Costar.

[0039] 2. Experimental methods and results

[0040] 2.1 Cell culture: 37°C, 5% CO 2 cultured in a humidified incubator. A DMEM medium containing 10% FBS, 100 U / mL of penicillin and streptomycin was used. Cells were subcultured after reaching 90% confluence, and the subculture ratio was 1 / 3 – 1 / 4.

[0041] 2.2 Virus culture: Take SPF chicken embryos aged 9 to 11 days, check them with an egg tester before inoculating the virus, and mark them at a position far away from the embryos, disinfect and punch holes, and inocu...

Embodiment 2

[0050] Embodiment 2: the evaluation of the anti-influenza virus broad-spectrum of nafuramide oxalate

[0051] This experiment detects that nafuramide oxalate is effective against influenza A subtype H1N1 strains, influenza A virus subtype H3N2 strains, influenza A virus subtype H1N1 amantadine-resistant strains, influenza A virus subtype H6N6 strains, and influenza A virus subtype H6N6 strains. Antiviral activity of influenza virus subtype H7N8 strain, influenza A virus subtype H9N2 strain and influenza B virus.

[0052] 1. The virus strains used in the experiment include: A / Human / Hubei / 1 / 2009(H1N1), A / human / Hubei / 3 / 2005(H3N2), A / WSN / S31N(H1N1), A / Duck / Hubei / 5 / 2010 (H6N6), A / Duck / Hubei / 216 / 1983 (H7N8), A / Chicken / Jiangsu / 1 / 2005 (H9N2), B / human / Huber / 1 / 2007.

[0053] 2. Divide MDCK cells into 1.5×10 4 Cells / well were seeded in 96-well cell culture plates, cultured in a 37°C cell culture incubator for 14-18 hours, and the cells were grown into a single layer before use. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of nafronyloxalate in preparing a medicine for preventing or treating influenza virus. According to the application, first, the cytotoxicity of nafronyloxalate to MDCK (madin-darby canine kidney) cells is detected, and results indicate that CC50 (50% cytotoxic concentration) of the nafronyloxalate is 238.1mu M; secondly, nafronyloxalate with non-cytotoxic concentration is selected to be subjected to anti-virus experiments, and results indicate that the small molecular compound has a remarkable anti-virus activity and is related to dose dependence; finally, the anti-virus activity of the nafronyloxalate to different types and sub-type influenza viruses is detected, and results indicate that nafronyloxalate can be used for inhibiting replication of all detected virus strains and has a dose dependent effect, and the anti-virus activity of the nafronyloxalate has a certain broad-spectrum. Therefore, the nafronyloxalate can be used as a novel anti-virus medicine for developing, and a novel way and means is provided to influenza treatment.

Description

technical field [0001] The invention relates to the application of nafuramide oxalate in the preparation of medicines for treating or preventing influenza virus, belonging to the technical field of medicine. Background technique [0002] Influenza viruses belong to the family Orthomyxoviridae, the genus Influenzavirus. According to the differences in the antigenic and genetic characteristics of the virion nucleoprotein (NP) and matrix protein (M), influenza viruses are divided into three types: A, B, and C, also known as A, B, and C. The whole genome of influenza A virus consists of eight single-stranded negative-strand RNAs of different sizes, named after segment 1 to segment 8, respectively. The full-length viral genome is about 13.6 kb, encoding 10 structural proteins (PB2, PB1, PA, HA, NP, NA, M1, M2, PB1-F2 and NS2 / NEP) and non-structural proteins (NS1). Influenza A viruses can be further divided into 17 H (H1-H17) and 10 N (N1-N10) subtypes according to the differenc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/341A61P31/16
Inventor 陈绪林安利伟
Owner 武汉威立得生物医药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com